62 related articles for article (PubMed ID: 22523221)
1. Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI).
Talaulikar D; Shadbolt B; Dahlstrom JE; McDonald A
J Hematol Oncol; 2009 Nov; 2():49. PubMed ID: 19930611
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact.
Devin J; Kassambara A; Bruyer A; Moreaux J; Bret C
J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31336593
[TBL] [Abstract][Full Text] [Related]
3. Commentary: Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma.
Sun Z; Tan R; Wu H; Fang X
Front Immunol; 2024; 15():1377221. PubMed ID: 38698842
[No Abstract] [Full Text] [Related]
4. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.
Tedder TF; Tuscano J; Sato S; Kehrl JH
Annu Rev Immunol; 1997; 15():481-504. PubMed ID: 9143697
[TBL] [Abstract][Full Text] [Related]
5. High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(-/low)/CD38- expression predicts poor survival in diffuse large B cell lymphoma.
Rijal S; Kok J; Coombes C; Smyth L; Hourigan J; Jain S; Talaulikar D
BMC Cancer; 2020 Nov; 20(1):1061. PubMed ID: 33143694
[TBL] [Abstract][Full Text] [Related]
6. Automated Analysis of Clinical Flow Cytometry Data: A Chronic Lymphocytic Leukemia Illustration.
Scheuermann RH; Bui J; Wang HY; Qian Y
Clin Lab Med; 2017 Dec; 37(4):931-944. PubMed ID: 29128077
[TBL] [Abstract][Full Text] [Related]
7. Computational flow cytometry: helping to make sense of high-dimensional immunology data.
Saeys Y; Van Gassen S; Lambrecht BN
Nat Rev Immunol; 2016 Jul; 16(7):449-62. PubMed ID: 27320317
[TBL] [Abstract][Full Text] [Related]
8. OpenCyto: an open source infrastructure for scalable, robust, reproducible, and automated, end-to-end flow cytometry data analysis.
Finak G; Frelinger J; Jiang W; Newell EW; Ramey J; Davis MM; Kalams SA; De Rosa SC; Gottardo R
PLoS Comput Biol; 2014 Aug; 10(8):e1003806. PubMed ID: 25167361
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometry bioinformatics.
O'Neill K; Aghaeepour N; Spidlen J; Brinkman R
PLoS Comput Biol; 2013; 9(12):e1003365. PubMed ID: 24363631
[TBL] [Abstract][Full Text] [Related]
10. RchyOptimyx: cellular hierarchy optimization for flow cytometry.
Aghaeepour N; Jalali A; O'Neill K; Chattopadhyay PK; Roederer M; Hoos HH; Brinkman RR
Cytometry A; 2012 Dec; 81(12):1022-30. PubMed ID: 23044634
[TBL] [Abstract][Full Text] [Related]
11. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
Wang C; Li W; Liu C; He H; Bai O
Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
[TBL] [Abstract][Full Text] [Related]
12. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
[TBL] [Abstract][Full Text] [Related]
13. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
14. B cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B-cell lymphoma.
Bashashati A; Johnson NA; Khodabakhshi AH; Whiteside MD; Zare H; Scott DW; Lo K; Gottardo R; Brinkman FS; Connors JM; Slack GW; Gascoyne RD; Weng AP; Brinkman RR
Am J Clin Pathol; 2012 May; 137(5):805-14. PubMed ID: 22523221
[TBL] [Abstract][Full Text] [Related]
15. Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study.
Yamamoto W; Nakamura N; Tomita N; Takeuchi K; Ishii Y; Takahashi H; Watanabe R; Takasaki H; Motomura S; Kobayashi S; Yokose T; Ishigatsubo Y; Sakai R
Leuk Lymphoma; 2014 Dec; 55(12):2721-7. PubMed ID: 24528218
[TBL] [Abstract][Full Text] [Related]
16. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
Keane C; Gill D; Vari F; Cross D; Griffiths L; Gandhi M
Am J Hematol; 2013 Apr; 88(4):273-6. PubMed ID: 23460351
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
